Hepatitis B combination therapy after liver cancer treatment
Part of Cancer, Digestive system clinical trials.
This trial tests a new two-drug combination for people with chronic hepatitis B who have had their liver cancer completely removed. The goal is to see if the combination can better control the hepatitis B virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have chronic hepatitis B (HBsAg positive for at least 6 months).
- You had surgery or ablation to remove liver cancer with no leftover tumor, and you have early stage (0 or A) liver cancer.
- You have been on hepatitis B antiviral pills (like tenofovir or entecavir) for at least one year and plan to stay on them.
- Your liver function is good (Child-Pugh A) and you have no major health issues like ascites or cirrhosis complications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an added hepatitis B immune medicine (HBV immunoglobulin) in people with chronic hepatitis B who have liver cancer and are planning surgery or a liver transplant. The goal is to see if giving this protection around the time of treatment can help prevent liver cancer from coming back or worsening.
This trial tests whether continuing antiviral therapy after surgery for hepatitis B-related liver cancer can improve outcomes. It focuses on patients with early-stage disease, good liver function, and no prior cancer treatments other than surgery or ablation.
This early-stage trial tests whether a drug called pegylated interferon alpha-2β can help prevent hepatitis B-related liver cancer from coming back after surgery. The drug aims to boost your immune system to fight any remaining cancer cells.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Hear when a new HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.